Illumina Inc is a leading biotechnology company that specializes in the development and manufacturing of advanced genomic sequencing technologies
The company focuses on providing innovative solutions for researchers and healthcare professionals, enabling them to analyze DNA, RNA, and other genomic materials with high accuracy and efficiency. Illumina’s cutting-edge sequencing platforms and reagents support a wide range of applications, including genomics research, clinical diagnostics, and personalized medicine, thereby playing a crucial role in advancing the field of genomics and improving human health.
Shares of genomics company Illumina (NASDAQILMN) fell 7.5% in the morning session after Barclays downgraded the stock to Sell and lowered the price target from $130 to $100. The firm cited several factors for the revision, including "growing uncertainty in China, rising competition from Roche in the clinical market, and weaker-than-expected elasticity in consumables demand."
Shares of genomics company Illumina (NASDAQILMN) fell 8.6% in the morning session after the company reported fourth-quarter results and provided full-year revenue guidance, which fell below Wall Street's expectations. The guidance did not account for the potential impact of the China Ministry of Commerce's decision to add the company to its 'unreliable entity list.'
Genomics company Illumina (NASDAQILMN) reported Q4 CY2024 results exceeding the market’s revenue expectations, but sales were flat year on year at $1.1 billion. On the other hand, the company’s full-year revenue guidance of $4.34 billion at the midpoint came in 1.2% below analysts’ estimates. Its non-GAAP profit of $0.86 per share was 6.9% below analysts’ consensus estimates.
It's a mixed session on Wall Street, with major indices struggling for direction as investors hold their breath ahead of a key jobs report set for Friday morning. The S&P 500 and the Nasdaq 100 edged up 0.3%, while the Dow Jones slipped 0.1% and small caps held steady.
Shares of genomics company Illumina (NASDAQILMN) fell 6.3% in the afternoon session after China put the company on its "unreliable entity" list, opening the door to possible sanctions. The move came after the Trump administration slapped a 10% tariff on Chinese goods. Financial filings in 2024 revealed that Illumina makes about 7% of its sales from China, and it's unclear whether China's action is a short-term reaction or one with longer consequences.
U.S. stocks advanced midday Tuesday, demonstrating resilience despite escalating geopolitical tensions and trade uncertainties between the world’s two largest economies.
